What is the Best Frontline Therapy for Patients with CLL and 17p Deletion

摘要: Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with significant variation in progression, response to therapy, and survival outcome. Deletions of 17p or mutations TP53 have been identified as one the poorest prognostic factors, being predictive short time for lack duration, overall survival. The treatment patients CLL has improved significantly development chemoimmunotherapy, but this benefit was not pronounced deletion. We compare various strategies used these patients, including FCR-like alemtuzumab, other antibody combinations, novel targeted therapies promising results. Allogeneic stem cell transplantation offers possibility long-term control should be considered early younger, transplant-eligible patients. current state therapy far from optimal resources applied studying therapeutic options who loss p53 function.